SCREENING OF DIABETIC RETINOPATHY
STATEMENT OF INTENT

These clinical practice guidelines (CPG) are meant to be guides for clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not necessarily guarantee the best outcome in every case. Every healthcare provider is responsible for the management of his/her unique patient based on the clinical picture presented by the patient and the management options available locally.

These guidelines were issued in 2011 and will be reviewed in 2015 or sooner if new evidence becomes available.

CPG Secretariat
Health Technology Assessment Section
Medical Development Division
Ministry of Health Malaysia
4th Floor, Block E1, Parcel E
62590 Putrajaya

Electronic version available on the following website:
http://www.moh.gov.my
http://www.acadmed.org.my
TABLE OF CONTENTS

LEVELS OF EVIDENCE SCALE AND GRADES OF RECOMMENDATION i
GUIDELINES DEVELOPMENT AND OBJECTIVE ii
GUIDELINES DEVELOPMENT GROUP v
REVIEW COMMITTEE vi
EXTERNAL REVIEWERS viii
ALGORITHM FOR SCREENING OF DIABETIC RETINOPATHY TO PREVENT BLINDNESS ix

1. INTRODUCTION 1

2. EPIDEMIOLOGY OF DIABETES MELLITUS AND DIABETIC RETINOPATHY 2
   2.1 Prevalence and Incidence of Diabetes Mellitus 2
       2.1.1 Adults 2
       2.1.2 Children and Adolescents 2
   2.2 Prevalence and Incidence of Diabetic Retinopathy 3
   2.3 Prevalence of Blindness and Sight Threatening Diabetic Retinopathy 3

3. RISK FACTORS 4

4. DIABETIC RETINOPATHY GRADING 5

5. ASSESSMENT OF DIABETIC RETINOPATHY 7
   5.1 Screening Tools 7
       5.1.1 Sensitivity and Specificity of Diabetic Retinopathy Screening Tools 7
       5.1.2 Agreement between Non-mydriatic Fundus Camera versus Ophthalmoscope and Mydriatic Fundus Camera 8
   5.2 Automated Diabetic Retinopathy Grading 8
   5.3 Pupillary Dilatation 9
   5.4. Examination and Grading of Diabetic Retinopathy by Healthcare Professionals 9
### 6. EXAMINATION SCHEDULE

6.1 Timing of First Screening

6.2 Follow-up Examination Schedule

6.3 Referral Criteria to Ophthalmologist

### 7. TREATMENT FOR DIABETIC RETINOPATHY

7.1 Current Treatment Modalities

7.2 Modifiable Risk Factors in Reducing Progression of Diabetic Retinopathy

### 8. IMPLEMENTING THE GUIDELINES

8.1. Existing Facilitators and Barriers in Applying Recommendations

8.2. Potential Resource Implications in Applying Recommendations

### REFERENCES

Appendix 1 SEARCH TERMS

Appendix 2 CLINICAL QUESTIONS

Appendix 3 FUNDUS APPEARANCE ACCORDING TO DIABETIC RETINOPATHY STAGES

Appendix 4 LIST OF HEALTH CLINICS WITH FUNDUS CAMERA IN MINISTRY OF HEALTH 2011

LIST OF ABBREVIATIONS

ACKNOWLEDGEMENT

DISCLOSURE STATEMENT

SOURCES OF FUNDING
### Levels of Evidence

<table>
<thead>
<tr>
<th>Level</th>
<th>Study design</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence from at least one properly randomised controlled trial</td>
</tr>
<tr>
<td>II-1</td>
<td>Evidence obtained from well-designed controlled trials without randomisation</td>
</tr>
<tr>
<td>II-2</td>
<td>Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one centre or group</td>
</tr>
<tr>
<td>II-3</td>
<td>Evidence from multiple time series with or without intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence</td>
</tr>
<tr>
<td>III</td>
<td>Opinions of respected authorities based on clinical experience; descriptive studies and case reports; or reports of expert committees</td>
</tr>
</tbody>
</table>

Source: US / Canadian Preventive Services Task Force

### Grades of Recommendation

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>At least one meta analysis, systematic review, or RCT, or evidence rated as good and directly applicable to the target population</td>
</tr>
<tr>
<td>B</td>
<td>Evidence from well conducted clinical trials, directly applicable to the target population, and demonstrating overall consistency of results; or evidence extrapolated from meta analysis, systematic review, or RCT</td>
</tr>
<tr>
<td>C</td>
<td>Evidence from expert committee reports, or opinions and / or clinical experiences of respected authorities; indicates absence of directly applicable clinical studies of good quality</td>
</tr>
</tbody>
</table>

Source: Modified from the Scottish Intercollegiate Guidelines Network (SIGN)

Note: The grades of recommendation relates to the strength of the evidence on which the recommendation is based. It does not reflect the clinical importance of the recommendation.
GUIDELINES DEVELOPMENT AND OBJECTIVES

GUIDELINES DEVELOPMENT

The Development Group for these Clinical Practice Guidelines (CPG) was from the Ministry of Health (MOH) and Ministry of Higher Education. They consisted of ophthalmologists, a paediatrician, an obstetrician & gynaecologist, a public health physician, a family medicine specialist, an optometrist, an assistant medical officer and a nursing sister. There was active involvement of the Review Committee during the process of development of these guidelines.

Literature search was carried out at the following electronic databases: Guidelines International Network (G-I-N); Centre for Reviews and Dissemination (CRD); PubMed; Ovid Medline, EBM Reviews - Cochrane Database of Systemic Reviews, EBM Reviews - Health Technology Assessment, Journals full text via OVID search engine (refer to Appendix 1 for Search Terms). In addition, the reference lists of all retrieved articles were searched to identify relevant studies. Experts in the field were also contacted to identify further studies. All searches were conducted between September 2009 and January 2011. Future CPG updates will consider evidence published after this cut-off date. The details of the search strategy can be obtained upon request from the CPG Seretariat.

Reference was also made to other guidelines on Diabetic Retinopathy such as The American Academy of Ophthalmology Preferred Practice Pattern Diabetic Retinopathy (2008) and National Health and Medical Research Council (NHMRC) Australia Guidelines for the Management of Diabetic Retinopathy (2008). These CPGs were evaluated using the Appraisal of Guidelines for Research and Evaluation (AGREE) prior to them being used as references.

The clinical questions were developed under three major subtopics and members of the Development Group were assigned individual questions within these subtopics (refer to Appendix 2 for Clinical Questions). The group members met a total of 16 times throughout the development of these guidelines. All literature retrieved was appraised by at least two members and presented in the form of evidence tables and discussed during Development Group meetings. All statements and recommendations formulated were agreed upon by both the Development Group and Review Committee. Where evidence was insufficient, the recommendations were made by consensus of both groups. These CPG are based largely on the findings of systematic reviews, meta-analyses and clinical trials, with local practices taken into consideration.
The articles were graded using the US/Canadian Preventive Services Task Force Level of Evidence (2001), while the grading of recommendation in these guidelines was modified from grades of recommendation of the Scottish Intercollegiate Guidelines Network (SIGN).

The draft guidelines were posted on the MOH Malaysia official website for comment and feedback. It had also been presented to the Technical Advisory Committee for CPG and the HTA-CPG Council, MOH Malaysia for review and approval.
OBJECTIVE

The objective of these CPG is to provide evidence-based recommendations in the screening of Diabetic Retinopathy. This would prevent or reduce the risk of visual loss, thereby maintaining or improving vision-related quality of life.

CLINICAL QUESTIONS

Refer to Appendix 2

TARGET POPULATION

All patients with Diabetes Mellitus including children and pregnant women

TARGET GROUP/USER

These guidelines are applicable to all healthcare professionals who are involved in the screening of Diabetic Retinopathy:

- Nurses/Assistant Medical Officers
- Family Medicine Specialists
- Optometrists
- General Practitioners/Medical Officers
- Physicians/ Paediatricians/ Obstetricians & Gynaecologists/ Endocrinologists
- Diabetic Support Groups
- Ophthalmologists

HEALTHCARE SETTING

Outpatient, inpatient and community settings
GUIDELINES DEVELOPMENT GROUP

Chairperson

Dr. Hajjah Nor Fariza Ngah  
Consultant Ophthalmologist  
Hospital Selayang  
Selangor

Members (alphabetical order)

Dr. Ang Ee Ling  
Ophthalmologist  
Hospital Pulau Pinang  
Pulau Pinang

Mdm. Nor Azizah Ismail  
Optometrist  
Hospital Sungai Buloh  
Selangor

Dr. Bavanandan Naidu Gopal  
Maternal Fetal Medicine Consultant  
Hospital Sultanah Bahiyah  
Kedah

Mr. Nik Mohd Kamil Nik Salleh  
Assistant Medical Officer  
Seremban Health Office  
Negeri Sembilan

Ms. Loong Ah Moi  
Nursing Sister  
Health Technology Assessment Section  
Ministry of Health Malaysia

Dr. Roslin Azni Abd. Aziz  
Ophthalmologist  
Hospital Selayang  
Selangor

Dr. Mohamad Aziz Salowi  
Ophthalmologist  
Hospital Umum Sarawak  
Sarawak

Dr. Shelina Oli Mohamed  
Ophthalmologist  
Hospital Selayang  
Selangor

Dr. Maziah Ishak  
Family Medicine Specialist  
Klinik Kesihatan Cheneh  
Terengganu

Dr. Ting Tzer Hwu  
Paediatric Endocrinologist  
Universiti Putra Malaysia  
Selangor

Dr. Mohd. Aminuddin Mohd. Yusof  
Public Health Physician  
Health Technology Assessment Section  
Ministry of Health Malaysia

Dr. Hajjah Zuraidah Haji Mustari  
Senior Consultant Ophthalmologist  
Hospital Sultanah Nur Zahirah  
Terengganu
REVIEW COMMITTEE

The draft guidelines were reviewed by a panel of independent expert referees from both public and private sectors including non-governmental organisation and patient advocate, who were asked to comment primarily on the comprehensiveness and accuracy in the interpretation of evidence supporting the recommendations in the guidelines.

Chairperson

Dr. Bethel Livingstone
Senior Consultant Ophthalmologist
Hospital Tuanku Ja’afar
Negeri Sembilan

Members (alphabetical order)

Dato’ Dr. Hj. Ahmad Razin Dato’ Hj. Ahmad Mahir
State Health Director
State Health Department
Perak

Dr. Anusiah Selvathurai
Senior Consultant Ophthalmologist
Hospital Malacca
Malacca

Dr. Angela Loo Voon Pei
Lecturer & Consultant Ophthalmologist
University Malaya Medical Centre
Kuala Lumpur

Dr. Chin Pik Kee
Consultant Ophthalmologist
Sunway Medical Centre
Selangor

Dr. Fatanah Ismail
Public Health Physician
Family Health Development Division
Department of Public Health
Ministry of Health Malaysia

Dr. Fuziah Md Zain
Consultant Paediatric Endocrinologist
Hospital Putrajaya
Putrajaya
Dr. Goh Pik Pin  
Director  
Clinical Research Centre  
Kuala Lumpur

Dr. Lim Kian Seng  
Consultant Ophtalmologist & Vitreoretinal Surgeon  
ISEC Sdn. Bhd.  
Kuala Lumpur

Dr. Mariam Ismail  
Senior Consultant Ophthalmologist  
Hospital Selayang  
Selangor

Mr. Murphy Chan Hian Kee  
Optometrist  
Malacca

Datin Dr. Rugayah Bakri  
Deputy Director  
Health Technology Assessment Section  
Medical Development Section  
Ministry of Health Malaysia

Dr. Vijay Ananda A/L K. Paramasvaran  
Representative  
Malaysian Diabetes Association

Prof. Dato’ Dr. Wan Mohamad Wan Bebakar  
Senior Lecturer & Senior Consultant Endocrinologist  
Hospital Universiti Sains Malaysia  
Kelantan

Dr. Zunaina Embong  
Senior Lecturer & Consultant Ophthalmologist  
Hospital Universiti Sains Malaysia  
Kelantan

Dr. Zanariah Hussein  
Consultant Endocrinologist  
Hospital Putrajaya  
Putrajaya
EXTERNAL REVIEWERS (alphabetical order)

The following External Reviewers provided feedback on the draft:

Dr. Ang Ee Lee
Paediatrician
Hospital Kuala Lumpur
Kuala Lumpur

Dr. Mastura Ismail
Family Medicine Specialist
Klinik Kesihatan Seremban 2
Negeri Sembilan

Dr. Dennis Kong
Consultant Ophthalmologist
Normah Medical Specialist Centre
Sarawak

Mdm. Mazita Mahmud
Optometrist
Hospital Kemaman
Terengganu

Dr. Noor Haliza Yusoff
Consultant Obstetrics & Gynaecology
Hospital Kuala Lumpur
Kuala Lumpur

Mr. Michael Anthonysamy
Assistant Medical Officer
Jabatan Kesihatan Wilayah Persekutuan
Kuala Lumpur

Dr. Kamilah Mohamed
Family Medicine Specialist
Klinik Kesihatan Bukit Payong
Terengganu

Assoc. Prof. Dr. Prut Hanutsaha
Senior Lecturer & Consultant Ophthalmologist
Faculty of Medicine
Ramathibodi Hospital, Bangkok, Thailand

Assoc. Prof. Dr. Kenneth Fong Choong Sian
Lecturer and Consultant Ophthalmologist
Faculty of Medicine
University of Malaya

Dato’ Dr. Ravindran Jegasothy
Senior Consultant Obstetrics & Gynaecology
Hospital Kuala Lumpur
Kuala Lumpur

Dr. Lai Yoon Kee
Consultant Ophthalmologist & Vitreo-Retinal Surgeon
Gleaneagles Medical Centre
Penang

Dr. Tunde Peto
Consultant Ophthalmologist
Moorefield Eye Centre
London, United Kingdom
Register all patients with diabetes

Assess and record visual acuity (VA)

Arrange for fundus photography/ophthalmoscopy

Perform fundus photography/complete fundus assessment

Ability to view/grade fundus

• No Diabetic Retinopathy (DR)
• Mild Non-Proliferative Diabetic Retinopathy (NPDR) without diabetic maculopathy
• Moderate NPDR without diabetic maculopathy

• Severe NPDR or worse
• Any diabetic maculopathy regardless of DR stages

Refer Ophthalmologist

Follow-up
1.0 INTRODUCTION

Diabetes Mellitus (DM) is an important public health concern. Globally there is a rising trend in the prevalence of DM due to many factors such as aging, urbanisation and increasing prevalence of obesity and physical inactivity. The International Diabetes Federation (IDF) predicts that the prevalence of DM in South East Asia will increase by two folds by the year 2025.\(^1\) The World Health Organization (WHO) has estimated that in the year 2030, Malaysia would have a total of 2.48 million people with DM.\(^2\) In Malaysia, the first National Health and Morbidity Survey I (NHMS I) conducted in 1986 reported a DM prevalence of 6.3%. This had risen to 8.3% in the NHMS II 1996 report. In the latest NHMS III 2006 report, the overall prevalence of DM was 11.6% and 14.9% in those aged above 18 and 30 years respectively. NHMS I and II involved subjects aged above 30 years while NHMS III was conducted among subjects above 18 years of age.\(^3\)

DM is a complex disease with end organ complications. However, good control of DM will prevent the onset or retard progression of the various complications including diabetic retinopathy (DR). In Malaysia, diabetic eye disease is the commonest cause of visual loss among adults of working age. Prevalence of DR is closely linked to the duration of DM. At diagnosis, less than 5% will have retinopathy while the prevalence rises to 40 - 50% after 10 years. Almost all patients with type 1 diabetes mellitus (T1DM) and more than 60% patients with type 2 diabetes mellitus (T2DM) have some degree of retinopathy after 20 years of the disease.\(^2\) Screening and early treatment can prevent substantial visual loss in many cases. Late presentation continues to be a major challenge of prevention and alleviation of blindness.

DM prevalence in Malaysia has dramatically risen to almost twice in the magnitude over the last decade. In view of this, efforts to control this chronic disease and early detection of complications such as DR should be intensified. This is important as DR is asymptomatic in its early stage when it is most easily amenable to treatment.

Therefore, a DR screening programme must be comprehensive, covering all individuals with DM in Malaysia.
2. EPIDEMIOLOGY OF DIABETES MELLITUS AND DIABETIC RETINOPATHY

WHO estimates that the global prevalence of DM will increase from 2.8% to 4.4% from the year 2000 to 2030.\textsuperscript{4, level III} Due to its chronicity, severity of complication and complexity of management, DM is a costly disease both for the affected individuals and the health sector as a whole.

DR is the leading cause of blindness and visual disability in adults of economically developed societies in the Western Pacific Region.\textsuperscript{1, level III} Its prevalence is closely linked to the duration of DM and varies among nations and ethnicity.\textsuperscript{5, level III}

2.1 Prevalence and Incidence of Diabetes Mellitus

2.1.1 Adults

The prevalence of DM among those aged more than 30 years in Malaysia has increased alarmingly from 6.3\% (1986) to 8.3\% (1996) and 14.9\% in 2006. There was also an increasing trend in the prevalence with age (2.0\% among those aged 18 - 19 years to 20.8 - 26.2\% among aged 50 - 64 years). Based on ethnicity, Indians have the highest prevalence followed by Malays and Chinese.\textsuperscript{3, level III} Among those with DM for more than 15 years, approximately 2\% became blind and 10\% developed severe visual handicap.\textsuperscript{1, level III}

It has been recommended that all DM patients should have at least a yearly eye examination.\textsuperscript{6, level III} However, the NHMS III 2006 reported that only 45\% of patients with known DM ever had an eye examination.\textsuperscript{3, level III}

2.1.2 Children and Adolescents

T1DM accounts for over 90\% of childhood and adolescent diabetes in most western countries.\textsuperscript{7, level III} The incidence of T1DM is on the increasing trend worldwide. The average annual increase is 4\% in Asia, 3.2\% in Europe and 5.3\% in North America.\textsuperscript{8, level III} In the Asian population, T2DM occurs at a much greater prevalence ranging between 50\% and 90\%.\textsuperscript{9, level III}
According to the Diabetes in Children and Adolescents Registry from April 2006 to June 2007, T1DM (69.2%) was more common than T2DM (17.5%). However there is no available data on the prevalence of DM in children and adolescents in Malaysia.

### 2.2 Prevalence and Incidence of Diabetic Retinopathy

DR is a leading complication of DM. The prevalence of DR worldwide ranges from 6.8 to 44.4% in patients with diabetes mellitus.

In Malaysia, the prevalence of DR from the 2007 Diabetic Eye Registry was 36.8% which was comparable to the prevalence of 35% found in the Singapore Malay Eye Study 2006. Other unpublished local data obtained from primary care screening centres showed a prevalence ranging between 12.3% and 16.9%.

In a study conducted in New South Wales, Australia, the prevalence of early DR in children less than 11 years was 8% as compared to 25% of adolescents older than 11 years. However, there is no retrievable data on the prevalence of DR in children and adolescents in Malaysia.

### 2.3 Prevalence of Blindness and Sight Threatening Diabetic Retinopathy

The prevalence of sight threatening DR ranges from 4.0 to 22.2%. In Malaysia, the National Eye Database (NED) 2007 and 2008 reported that the proportion of patients with sight threatening DR was 15.6% and 11.5% respectively. The proportion of patients with blindness was 9.0%.
3. RISK FACTORS

There are many risk factors for DR. The duration of DM is significantly associated with the development and severity of DR with odds ratio (OR) ranging from 1.07 to 8.62.\textsuperscript{5, level III; 20 - 21, level III; 23, level III, 25}

Significant systemic risk factors include hypertension and high HbA\textsubscript{1c}, systolic blood pressure (SBP), pulse pressure, serum lipoprotein level and body mass index (BMI).\textsuperscript{5, level III; 20 - 21, level III; 22, level II-2; 23 - 24, level III; 25; 26, level III} Other documented risk factors include renal disease/nephropathy, genetic factors, high waist-hip-ratio (abdominal obesity), upper socioeconomic status, urban residence, higher plasma total homocysteine level, male gender, insulin treatment and pregnancy.\textsuperscript{20, level III; 23 - 24, level III ; 25; 27, level III}

The risk factors for sight threatening DR are chronic kidney disease (OR=4.45, 95% CI 2.18 to 9.07), previous stroke (OR=3.74, 95% CI 1.24 to 11.26), cardiovascular disease (OR=2.23, 95% CI 1.08 to 4.62),\textsuperscript{5, level III} duration of DM (OR=1.38, 95% CI 1.02 to 1.87)\textsuperscript{21, level III} and hypercholesterolemia.\textsuperscript{25}

**Recommendation**

- Screening for diabetic retinopathy should be done in all patients with diabetes mellitus. (Grade C)
4. DIABETIC RETINOPATHY GRADING

To improve communication worldwide between ophthalmologists and primary healthcare providers in managing patients with DM, an international clinical disease severity scale was developed for DR and Diabetic Macula Oedema (DME) (refer to Table 1). This scale is based on the Early Treatment for Diabetic Retinopathy Study (ETDRS) Classification of DR and on the data collected in clinical trials and epidemiologic studies of DR.

### Table 1: International Clinical Diabetic Retinopathy and Diabetic Macula Oedema Disease Severity Scale

<table>
<thead>
<tr>
<th>RETINOPTHATY STAGE</th>
<th>FINDINGS ON OPHTHALMOSCOPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>No apparent retinopathy</td>
<td>No abnormalities</td>
</tr>
<tr>
<td>Mild non-proliferative DR (NPDR)</td>
<td>Microaneurysms only</td>
</tr>
<tr>
<td>Moderate NPDR</td>
<td>More than just microaneurysms but less than severe NPDR</td>
</tr>
<tr>
<td>Severe NPDR</td>
<td>Any of the following:</td>
</tr>
<tr>
<td></td>
<td>1. More than 20 intraretinal haemorrhages in each of 4 quadrants</td>
</tr>
<tr>
<td></td>
<td>2. Definite venous beading in 2 or more quadrants</td>
</tr>
<tr>
<td></td>
<td>3. Prominent intraretinal microvascular abnormalities in 1 or more quadrants AND no signs of proliferative retinopathy</td>
</tr>
<tr>
<td>Proliferative DR (PDR)</td>
<td>One of the following:</td>
</tr>
<tr>
<td></td>
<td>1. Neovascularisation</td>
</tr>
<tr>
<td></td>
<td>2. Vitreous/preretinal haemorrhage</td>
</tr>
<tr>
<td>Advanced Diabetic Eye Disease (ADED)</td>
<td>One of the following:</td>
</tr>
<tr>
<td></td>
<td>1. Formation of fibrovascular tissue proliferation</td>
</tr>
<tr>
<td></td>
<td>2. Traction retinal detachment due to formation of posterior vitreous detachment</td>
</tr>
<tr>
<td></td>
<td>3. Dragging of retinal/distortion</td>
</tr>
<tr>
<td></td>
<td>4. Rhegmatogenous retinal detachment</td>
</tr>
</tbody>
</table>
### Macula Oedema

<table>
<thead>
<tr>
<th>MACULA OEDEMA</th>
<th>FINDINGS ON OPHTHALMOSCOPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>No retinal thickening or hard exudates in posterior pole</td>
</tr>
</tbody>
</table>
| Present       | • Mild – some retinal thickening or hard exudates in posterior pole but distant from the macula  
                • Moderate – retinal thickening or hard exudates approaching the centre of the macula but not involving the centre  
                • Severe – retinal thickening or hard exudates involving the centre of the macula |


Examples of fundus appearance according to DR Stages are shown in **Appendix 3.**
5. ASSESSMENT OF DIABETIC RETINOPATHY

A variety of screening modalities are available in detecting and classifying DR. Ophthalmoscopy is the most commonly used technique to screen for DR. However, non-mydriatic digital fundus photography is now being widely used. There is a wide variation in the sensitivities and specificities of different screening modalities performed by different screeners.

5.1 Screening Tools

The instruments that can be used for screening are:

- Direct ophthalmoscope
- PAN-ophthalmoscope
- Binocular indirect ophthalmoscope (BIO)
- Slit lamp biomicroscope
- Mydriatic fundus camera
- Non-mydriatic fundus camera

5.1.1 Sensitivity and Specificity of Diabetic Retinopathy Screening Tools

The UK National Institute for Clinical Excellence (NICE) recommends that DR screening modalities should have a sensitivity of at least 80%, a specificity of at least 95% and a technical failure rate of no greater than 5%.28

Table 2 describes the diagnostic accuracy of different screening tools. Non-mydriatic fundus camera has high sensitivity and specificity. It eliminates the need for pupillary dilatation, promoting compliance, efficiency and safety. The findings by Aptel F et al showed that at least one field photo assessment was sufficient to detect DR. However, the Training Module for DR Screening in Malaysia recommends two fields photo assessment.29, level III
Table 2: Sensitivity and Specificity of DR Screening Tools

<table>
<thead>
<tr>
<th>SCREENING TOOL</th>
<th>SENSITIVITY</th>
<th>SPECIFICITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct ophthalmoscope(^{25})</td>
<td>45.0 - 98.0%</td>
<td>62.0 - 100%</td>
</tr>
<tr>
<td>Slit lamp biomicroscope(^{30,, \text{level II-2}})</td>
<td>87.4%</td>
<td>94.9%</td>
</tr>
<tr>
<td>Mydriatic fundus camera(^{25})</td>
<td>73.0 - 96.0%</td>
<td>68.0 - 99.0%</td>
</tr>
<tr>
<td>Non-mydriatic fundus camera(^{31,, \text{level II-2}})</td>
<td>92.0%</td>
<td>97.0%</td>
</tr>
</tbody>
</table>

5.1.2 Agreement between Non-mydriatic Fundus Camera versus Ophthalmoscope and Mydriatic Fundus Camera

As a screening tool, non-mydriatic fundus camera has good inter-rater reliability with ophthalmoscope (\(\kappa=0.90\))\(^{31,\, \text{level II-2}}\) and mydriatic fundus camera (\(\kappa=0.80\))\(^{32,\, \text{level I}}\)

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Non-mydriatic fundus camera should be used as a screening tool for diabetic retinopathy (DR) when possible. (Grade A)</td>
</tr>
<tr>
<td>○ Two fields fundus photo assessment should be done. (Grade C)</td>
</tr>
<tr>
<td>• When there is no access to fundus camera, ophthalmoscope should be used for screening of DR. (Grade C)</td>
</tr>
</tbody>
</table>

5.2 Automated Diabetic Retinopathy Grading

Automated grading of DR is a growing research field aimed at decreasing the burden of grading. Various individual softwares have been developed.\(^{33\, -\, 34,\, \text{level II-2};\, 35\, -\, 36,\, \text{level III}}\) However, further evaluation and validation is required for local use.
5.3 Pupillary Dilatation

Non-mydriatic fundus photography generally does not require pupil dilatation if performed in an adequately darkened room. However, in cases of small pupil and ungradable photos, pupillary dilatation can increase the sensitivity of screening by over 50%. Those performing DR screening should be aware of the possibility of inducing acute angle closure glaucoma in high risk individuals (history of glaucoma and shallow anterior chamber). The use of tropicamide 1% alone has not been reported to cause this complication.37, level III

Those intending to use tropicamide 1% should be aware of the possible side effects.

**Recommendation**

- Tropicamide 1% should be used for pupillary dilatation in selected cases by trained personnel. (Grade C)

5.4. Examination and Grading of Diabetic Retinopathy by Healthcare Professionals

The screening and grading of DR can be performed with high accuracy by:

- Doctors (family medicine specialists, general practitioners and medical officers)
- Optometrists
- Assistant medical officers and nurses

All healthcare personnel need proper training before they can be privileged for DR screening so as to increase the interpretation and grading accuracy. Studies have shown that the sensitivity and specificity of interpretation increased after training.38 - 42, level III; 41, level III Jackson CL et al reported that brief training intervention had increased the accuracy of interpretation from 24% to 94%.41, level III

In another study, trained primary care clinicians showed appropriate referral to the ophthalmologist with a sensitivity of 89.8% and a specificity of 93%.38, level III
Retinal screeners and graders require specific training, accreditation and regular performance assessment. Training module should include:

- Clinical knowledge and skills
- Imaging and computer skills
- Operational issues
- Fundus grading

A Training Steering Group has been established by the Ministry of Health (MOH) Malaysia. This group has produced a training manual and developed a training curriculum. The MOH has accredited the training curriculum and training materials. Training should be adapted to the local setting to enable the trainees to handle available and relevant equipments.

**Recommendation**

- All diabetic retinopathy (DR) screeners must undergo appropriate and standardised training as per DR screening training module. *(Grade C)*
6. EXAMINATION SCHEDULE

Early detection of sight threatening retinopathy by regular examination is the key to reduce visual loss and blindness from DR. Due to the sight threatening potential of DR and the availability of methods to slow down the rate of disease progression, a proper screening at an appropriate time is recommended.25

6.1 Timing of First Screening

The initial fundus examination for DR varies according to the types of DM:

- **Adults T1DM**
  Adults with T1DM should have their first screening within three to five years after the initial diagnosis.43; 44, level III

- **Adults T2DM**
  The time of onset of T2DM is often difficult to determine and may precede the diagnosis by a number of years. Therefore, patients should have their first fundus examination at the time of diagnosis.43; 44, level III

- **Pregnant Women with Pre-existing DM**
  DR can worsen during pregnancy because of changes in metabolic status. Individuals with DM planning for pregnancy should have their eyes examined prior to conception and counselled on the risk of development and progression of DR.25; 43

- **Gestational DM (GDM)**
  GDM is an abnormal glucose intolerance first detected during pregnancy. In general, DR screening is not required for GDM.25; 43 However, if GDM is diagnosed in the first trimester of pregnancy, screening should be as per pre-existing DM.
• **Children and Adolescents**
  Incidence of DR in young children is negligibly small and therefore children younger than 9 years old do not require screening for DR.\(^4^5\), level III International Society for Paediatric & Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines 2009 recommends timing of first screening as follows:\(^4^6\), level III

  a) **T1DM:**
  - At age 9 years with 5 years of diabetes duration
  - At age 11 years with 2 years of diabetes duration

  b) **T2DM:**
  - At the time of diagnosis

**Recommendation**

- First screening for diabetic retinopathy (DR) should be done at:
  - Adults type 1 diabetes mellitus (T1DM) - up to 3 years after diagnosis
  - Adults type 2 diabetes mellitus (T2DM) - at time of diagnosis
  - Pregnant women with
    - Pre-existing diabetes mellitus (DM) - prior to planned pregnancy
    - Gestational DM (GDM) diagnosed in the first trimester - at the time of diagnosis. Otherwise not required.
  - Children T1DM
    - At age 9 years with 5 years of DM duration
    - At age 11 years with 2 years of DM duration
  - Children T2DM - at time of diagnosis (Grade C)
6.2 Follow-up Examination Schedule

Individuals with DM should be screened at least every two years. High risk individuals (longer duration of diabetes or poor control of blood sugar, blood pressure or serum lipid) should be examined at least annually.\textsuperscript{25}

The examination should include:

- Visual acuity assessment (Snellen chart and equivalent)
- Fundus photography or dilated fundus examination

Individuals with any signs of NPDR should be examined at 6 - 12 monthly intervals. Earlier follow-up may be required in:\textsuperscript{43, 44, level III}

- High risk groups
- Presence of renal complications
- Progression of DR

The recommended intervals for eye examination for patients with DM are provided in Table 3.

Table 3: Recommended Follow-up Schedule

<table>
<thead>
<tr>
<th>STAGE OF RETINOPATHY</th>
<th>FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td>No DR</td>
<td>12 - 24 months</td>
</tr>
<tr>
<td>Mild NPDR without maculopathy</td>
<td>9 - 12 months</td>
</tr>
<tr>
<td>Moderate NPDR without maculopathy</td>
<td>6 months</td>
</tr>
<tr>
<td>Mild/Moderate NPDR with maculopathy</td>
<td></td>
</tr>
<tr>
<td>Severe NPDR without maculopathy</td>
<td>Refer to Ophthalmologist</td>
</tr>
<tr>
<td>Any maculopathy</td>
<td></td>
</tr>
<tr>
<td>Proliferative DR</td>
<td>Refer urgently to Ophthalmologist</td>
</tr>
<tr>
<td>Advanced Diabetic Eye Disease (ADED)</td>
<td></td>
</tr>
<tr>
<td>No DR to Mild NPDR In Pregnant Women</td>
<td>Every 3 months</td>
</tr>
<tr>
<td>Moderate NPDR or Worse In Pregnant Women</td>
<td>Refer to Ophthalmologist</td>
</tr>
</tbody>
</table>

Sources:
6.3 Referral Criteria to Ophthalmologist

The ultimate aim for screening of DR is to detect sight threatening DR and to ensure timely treatment in order to prevent vision loss. Appropriate referral to the ophthalmologist should be done.

Criteria for referral are:

- Any level of Diabetic Maculopathy
- Severe NPDR
- Any PDR
- Unexplained visual loss
- If screening examination cannot be performed including ungradable fundus photo

The urgency of referral is as shown in Table 4.

### Table 4: Criteria for Urgent Referral

<table>
<thead>
<tr>
<th>URGENCY OF REFERRAL</th>
<th>OCULAR FEATURES</th>
</tr>
</thead>
</table>
| Emergency (same day referral) | • Sudden severe visual loss  
|                          | • Symptoms or signs of acute retinal detachment                                      |
| Within 1 week           | • Presence of retinal new vessels  
|                          | • Preretinal haemorrhage  
|                          | • Vitreous haemorrhage  
|                          | • Rubeosis iridis                                                                   |
| Within 4 weeks          | • Unexplained drop in visual acuity  
|                          | • Any form of maculopathy  
|                          | • Severe NPDR  
|                          | • Worsening retinopathy                                                            |


**Recommendation**

- Examination schedule and urgency of referral to an ophthalmologist should be based on the grade and severity of diabetic retinopathy as well as the presence of risk factors. **(Grade C)**
## 7.0 TREATMENT FOR DIABETIC RETINOPATHY

### 7.1 Current Treatment Modalities

Early detection of DR is important as it is reversible. There are many treatment modalities available (refer to **Table 5**). Laser photocoagulation remains the standard practice for treating DR. Stages of DR which require treatment includes severe NPDR, PDR, ADED and DME.

**Table 5: Summary of Treatment for Diabetic Retinopathy**

<table>
<thead>
<tr>
<th>STAGE OF DR</th>
<th>MODE OF TREATMENT</th>
</tr>
</thead>
</table>
| DME         | • Laser - focal/ grid  
|             | • Intraocular steroids*  
|             | • Intraocular anti-vascular endothelial growth factor (anti-VEGF)* |
| Severe NPDR | • Laser - scattered pan-retinal photocoagulation (PRP) |
| PDR         | • Laser - PRP |
| ADED        | • Intraocular steroids  
|             | • Intraocular anti-vascular endothelial growth factor (anti-VEGF)  
|             | • Vitrectomy |

*For refractory DME
The mainstay of current treatment involves risk factor modification by controlling blood glucose, blood pressure and serum lipids as shown in Table 6. Potential alternative therapeutic approaches that directly target diabetic microvascular complications include:\textsuperscript{25, 47}

- Antiplatelet agents
- Advanced glycation end (AGE) product inhibitors
- Aldose reductase inhibitors (ARIs)
- Protein kinase C (PKC) inhibitors
- Angiotensin converting enzyme (ACE) inhibitors
- Fenofibrate

### Table 6: Target Level of Modifiable Risk Factors in Adults

<table>
<thead>
<tr>
<th>RISK FACTOR</th>
<th>TARGET LEVEL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glycaemic Control</strong></td>
<td></td>
</tr>
<tr>
<td>Fasting</td>
<td>4.4 - 6.1 mmol/L</td>
</tr>
<tr>
<td>Non-fasting</td>
<td>4.4 - 8.0 mmol/L</td>
</tr>
<tr>
<td>HbA\textsubscript{1c}</td>
<td>&lt;6.5%</td>
</tr>
<tr>
<td><strong>Blood Pressure</strong></td>
<td></td>
</tr>
<tr>
<td>Normal Renal Function</td>
<td>≤130/80 mmHg</td>
</tr>
<tr>
<td>Renal Impairment/ micro- or macroalbuminuria</td>
<td>≤120/75 mmHg</td>
</tr>
<tr>
<td><strong>Lipids</strong></td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>≤1.7 mmol/L</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>≥1.1 mmol/L</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>≤2.6 mmol/L</td>
</tr>
</tbody>
</table>

Source: Ministry of Health Malaysia. Management of Type 2 Diabetes Mellitus (Fourth Edition). Putrajaya: MOH; 2009

Other modalities of risk factor modification include diet, exercise and stop smoking.\textsuperscript{48}
8.0 IMPLEMENTING THE GUIDELINES

This chapter provides advice on the resource implications associated with implementing the key recommendations and advice on proposed clinical audit indicators for quality management to aid implementation.

Implementation of these CPG is an essential part of clinical governance. It should cater to the local individual hospitals, health clinics and community based on both economic and non-economic considerations. Mechanisms should be in place to review the existing healthcare system as compared to the CPG recommendations. Any differences should be assessed and addressed appropriately.

Important issues that should be considered when implementing these CPG in Malaysia are:-

- Establishment of a screening programme
- Proper DR database
- Adequate training and privileging of screeners and graders
- Availability of screening tools
- Co-ordinated referral system & availability of resources for necessary treatment

8.1 Existing Facilitators and Barriers in Applying Recommendations

The implementation of the CPG will be facilitated by the existing DR Screening Training Module of the MOH Malaysia. The module has been established since 2008 and involves the training of family medicine specialists, medical officers, optometrists, assistant medical officers and nurses. However, the Development Group will ensure that the contents of this training module will be in tandem with the recommendations in the CPG.

There are three barriers in applying recommendations of the CPG in the local context:

i. Patient factors
   - Lack of awareness of the possible complications of DM to the eye as DR may remain asymptomatic
   - Poor access to eye care services
   - Different cultural beliefs

ii. Healthcare professional factors
   - Limited knowledge and/or poor attitude
   - Limited resources
   - High turnover of trained screeners and graders
   - Lack of utilisation of screening tools
iii. Health services factors

- Lack of linkages between services and providers
- Lack of recalls or reminders for defaulters
- Long waiting list for first screening and referral to see ophthalmologist
- Lack of optimisation of fundus cameras

With the availability of these national evidence-based CPG, the current nation-wide screening programme will be strengthened to prevent blindness among those with DM.

8.2 Potential Resource Implications in Applying Recommendations

In implementing the CPG, the Development Group recommends strengthening of the existing training module on DR screening. Financial allocation is proposed to individual hospitals, health clinics and communities to achieve adequate access to eye screening.

In view of the low percentage of DM patients screened for DR annually, the development group proposes the following clinical audit indicators for quality management as part of ensuring the implementation of recommendations in the CPG:

- Percentage of T2DM patients screened for DR for the first time = Number of T2DM patients screened for DR for the first time within a year / Total number of newly registered T2DM patients within the same year x 100%

- Percentage of ungradable fundus photo = Number of patients with ungradable fundus photo within a year / Total number of patients’ fundus photos taken within the same year x 100%

- Percentage of diabetics screened with sight threatening DR = Number of diabetics screened with sight threatening DR within a year / Total number of diabetics screened for DR within the same year x 100%
REFERENCES
REFERENCES


47. Ministry of Health Malaysia. Management of Type 2 Diabetes Mellitus (Fourth Edition). Putrajaya: MOH; 2009

APPENDICES
Appendix 1

SEARCH TERMS

The following MeSH terms or free text terms were used either singly or in combination:

Appendix 2

CLINICAL QUESTIONS

1. What is the prevalence of Type 1 DM and Type 2 DM in Malaysia and worldwide?

2. What is the prevalence of diabetic retinopathy in Type 1 and Type 2 DM in Malaysia and worldwide?

3. What is the prevalence of sight threatening DR or blindness due to diabetic retinopathy in Malaysia and worldwide?

4. Is there any difference in the risk of diabetic retinopathy for the different types of diabetes?

5. What are the current grading systems for diabetic retinopathy?

6. What are the sensitivity and specificity of screening tools to detect diabetic retinopathy?
   i. Direct ophthalmoscope
   ii. PAN-ophthalmoscope
   iii. BIO
   iv. Slit lamp
   v. Fundus camera - mydriatic versus nonmydriatic

7. Is automated grading of diabetic retinopathy as efficient as manual grading?

8. When should the pupil be dilated and what are the potential side effects of pupillary dilation?

9. Who can perform examination and grade the status of diabetic retinopathy?

10. What are the criteria for referral of DR to the ophthalmologist?

11. What are the most appropriate timing and frequency of eye examinations in people with DM?
   i. Established diabetics who are planning to get pregnant or who are already pregnant
   ii. Children and adolescents
   iii. Adults

12. What are the treatments for diabetic retinopathy?

13. Are there new modalities in treating diabetic retinopathy?
Appendix 3

FUNDUS APPEARANCE ACCORDING TO DR STAGES

No DR

Mild NPDR

Moderate NPDR

Severe NPDR
SCREENING OF DIABETIC RETINOPATHY

PDR

Moderate and Severe Diabetic Maculopathy

ADED and Vitreous Haemorrhage

Ungradable Photos
### LIST OF HEALTH CLINICS WITH FUNDUS CAMERA IN MINISTRY OF HEALTH 2011

<table>
<thead>
<tr>
<th>No.</th>
<th>State/District</th>
<th>Health Clinic</th>
<th>Total Fundus Camera</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><strong>Perlis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kangar</td>
<td>Klinik Kesihatan Kangar</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Arau</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td><strong>Kedah</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kubang Pasu</td>
<td>Klinik Kesihatan Kepala Batas</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Padang Terap</td>
<td>Klinik Kesihatan Naka</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Kota Setar</td>
<td>Klinik Kesihatan Pokok Sena</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Simpang Kuala</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pendang</td>
<td>Klinik Kesihatan Pendang</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yan</td>
<td>Klinik Kesihatan Guar Chempedak</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sik</td>
<td>Klinik Kesihatan Jeniang</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuala Muda</td>
<td>Klinik Kesihatan Bandar Sungai Petani</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Baling</td>
<td>Klinik Kesihatan Tawar</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kulim</td>
<td>Klinik Kesihatan Kulim</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Padang Serai</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bandar Baharu</td>
<td>Klinik Kesihatan Serdang</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td><strong>Pulau Pinang</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seberang Perai Utara</td>
<td>Klinik Kesihatan Butterworth</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Seberang Perai Tengah</td>
<td>Klinik Kesihatan Seberang Jaya</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seberang Perai Selatan</td>
<td>Klinik Kesihatan Nibong Tebal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Timur Laut</td>
<td>Klinik Kesihatan Jalan Perak</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td><strong>Perak</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kinta</td>
<td>Klinik Kesihatan Jelapang</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Greentown</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Larut Matang</td>
<td>Klinik Kesihatan Taiping</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Manjung</td>
<td>Klinik Kesihatan Sitiawan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hilir Perak</td>
<td>Klinik Kesihatan Hutan Melintang</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Batang Padang</td>
<td>Klinik Kesihatan Tanjung Malim</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuala Kangsar</td>
<td>Klinik Kesihatan Padang Rengas</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kerian</td>
<td>Klinik Kesihatan Bagan Serai</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>State/District</td>
<td>Health Clinic</td>
<td>Total Fundus Camera</td>
</tr>
<tr>
<td>-----</td>
<td>------------------------------</td>
<td>----------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>5.</td>
<td>Selangor</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gombak</td>
<td>Klinik Kesihatan Taman Ehsan</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Hulu Langat</td>
<td>Klinik Kesihatan Kajang</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Klang</td>
<td>Klinik Kesihatan Pandamaran</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuala Langat</td>
<td>Klinik Kesihatan Telok Datuk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuala Selangor</td>
<td>Klinik Kesihatan Kuala Selangor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sabak Bernam</td>
<td>Klinik Kesihatan Sungai Besar</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hulu Selangor</td>
<td>Klinik Kesihatan Serendah</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>WP Kuala Lumpur &amp; Putrajaya</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Putrajaya</td>
<td>Klinik Kesihatan Putrajaya</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Kuala Lumpur</td>
<td>Klinik Kesihatan Jinjang</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Cheras Baru</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Tanglin</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Negeri Sembilan</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seremban</td>
<td>Klinik Kesihatan Seremban</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Ampangan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Rantau</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuala Pilah</td>
<td>Klinik Kesihatan Kuala Pilah</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Juasseh</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jelebu</td>
<td>Klinik Kesihatan Jelebu</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jempol</td>
<td>Klinik Kesihatan Bahau</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Palong 4,5,6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rembau</td>
<td>Klinik Kesihatan Rembau</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tampin</td>
<td>Klinik Kesihatan Tampin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Port Dickson</td>
<td>Klinik Kesihatan Port Dickson</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Malacca</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Malacca Tengah</td>
<td>Klinik Kesihatan Ayer Keroh</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alor Gajah</td>
<td>Klinik Kesihatan Masjid Tanah</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jasin</td>
<td>Klinik Kesihatan Selandar</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Umbai</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jabatan Pesakit Luar Jasin</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>State/District</td>
<td>Health Clinic</td>
<td>Total Fundus Camera</td>
</tr>
<tr>
<td>-----</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>9.</td>
<td>Johor</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Johor Bahru</td>
<td>Klinik Kesihatan Pasir Gudang</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Mahmodiah</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Muar</td>
<td>Klinik Kesihatan Bandar Maharani</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Parit Jawa, Muar</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Paya Mas, Muar</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Batu Pahat</td>
<td>Klinik Kesihatan Batu Pahat</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Kluang</td>
<td>Klinik Kesihatan Mengkibol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pontian</td>
<td>Klinik Kesihatan Pontian</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Segamat</td>
<td>Klinik Kesihatan Segamat</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kota Tinggi</td>
<td>Jabatan Pesakit Luar Kota Tinggi</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mersing</td>
<td>Klinik Kesihatan Endau</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ledang</td>
<td>Klinik Kesihatan Paya Mas</td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td>Pahang</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuantan</td>
<td>Klinik Kesihatan Bandar Kuantan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Balok</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Jaya Gading</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Temerloh</td>
<td>Klinik Kesihatan Temerloh</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Bera</td>
<td>Klinik Kesihatan Triang</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lipis</td>
<td>Klinik Kesihatan Benta</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maran</td>
<td>Klinik Kesihatan Maran (tidak berfungsi)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Bandar Jengka</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rompin</td>
<td>Klinik Kesihatan Kuala Rompin</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>State/District</td>
<td>Health Clinic</td>
<td>Total Fundus Camera</td>
</tr>
<tr>
<td>-----</td>
<td>----------------</td>
<td>---------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>11.</td>
<td><strong>Terengganu</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuala Terengganu</td>
<td>Jabatan Pesakit Luar Hospital Sultanah Nur Zahirah</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Hiliran</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Batu Rakit</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dungun</td>
<td>Klinik Kesihatan Ketengah Jaya</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marang</td>
<td>Klinik Kesihatan Marang</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Bukit Payong</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Besut</td>
<td>Klinik Kesihatan Kuala Besut</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Setiu</td>
<td>Klinik Kesihatan Pemaisuri</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kemaman</td>
<td>Klinik Kesihatan Kerteh</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hulu Terengganu</td>
<td>Klinik Kesihatan Aji</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Kuala Berang</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Tengkawang</td>
<td></td>
</tr>
<tr>
<td>12.</td>
<td><strong>Kelantan</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gua Musang</td>
<td>Klinik Kesihatan Gua Musang</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuala Krai</td>
<td>Klinik Kesihatan Kuala Krai</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pasir Puteh</td>
<td>Klinik Kesihatan Selising</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tumpat</td>
<td>Klinik Kesihatan Wakaf Baru</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jeli</td>
<td>Klinik Kesihatan Jeli</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Ayer Lanas</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kota Bharu</td>
<td>Klinik Kesihatan Kota Bharu</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Keterah</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Machang</td>
<td>Klinik Kesihatan Labok</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pasir Mas</td>
<td>Klinik Kesihatan Pasir Mas</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Tendong</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tanah Merah</td>
<td>Klinik Kesihatan Batu Gajah</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bachok</td>
<td>Klinik Kesihatan Bachok</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klinik Kesihatan Gunong</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>State/District</td>
<td>Health Clinic</td>
<td>Total Fundus Camera</td>
</tr>
<tr>
<td>-----</td>
<td>----------------</td>
<td>---------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>13.</td>
<td><strong>Sabah</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kota Kinabalu</td>
<td>Klinik Kesihatan Luyang</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Sandakan</td>
<td>Klinik Kesihatan Sandakan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Penampang</td>
<td>Klinik Kesihatan Penampang</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td><strong>Sarawak</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Miri</td>
<td>Klinik Kesihatan Miri</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Sibu</td>
<td>Klinik Kesihatan Lanang</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuching</td>
<td>Klinik Kesihatan Jalan Masjid, Klinik Kesihatan Sentosa</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td>107</td>
</tr>
</tbody>
</table>
### LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE</td>
<td>Angiotensin Converting Enzyme (ACE) Inhibitors</td>
</tr>
<tr>
<td>ADED</td>
<td>Advanced Diabetic Eye Disease</td>
</tr>
<tr>
<td>AGE</td>
<td>Advanced Glycation End (AGE) Product Inhibitors</td>
</tr>
<tr>
<td>Anti-VEGF</td>
<td>Anti-Vascular Endothelial Growth Factor</td>
</tr>
<tr>
<td>ARIs</td>
<td>Aldose Reductase Inhibitors (ARIs)</td>
</tr>
<tr>
<td>BIO</td>
<td>Binocular Indirect Ophthalmoscope</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence Interval</td>
</tr>
<tr>
<td>CPG</td>
<td>Clinical Practice Guidelines</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>DR</td>
<td>Diabetic Retinopathy</td>
</tr>
<tr>
<td>DRS</td>
<td>Diabetic Retinopathy Screening</td>
</tr>
<tr>
<td>ETDRS</td>
<td>Early Treatment for Diabetic Retinopathy Study</td>
</tr>
<tr>
<td>GDM</td>
<td>Gestational Diabetes Mellitus</td>
</tr>
<tr>
<td>IDF</td>
<td>The International Diabetes Federation</td>
</tr>
<tr>
<td>MOH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>NED</td>
<td>National Eye Database</td>
</tr>
<tr>
<td>NPDR</td>
<td>Non-Proliferative Diabetic Retinopathy</td>
</tr>
<tr>
<td>OR</td>
<td>Odds Ratio</td>
</tr>
<tr>
<td>PDR</td>
<td>Proliferative Diabetic Retinopathy</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein Kinase C (PKC) Inhibitors</td>
</tr>
<tr>
<td>PRP</td>
<td>Pan-Retinal Photocoagulation</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised Controlled Trial</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic Blood Pressure</td>
</tr>
<tr>
<td>T1DM</td>
<td>Type 1 Diabetes Mellitus</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type 2 Diabetes Mellitus</td>
</tr>
<tr>
<td>VA</td>
<td>Visual Acuity</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENT

The members of Development Group of these guidelines would like to express their gratitude and appreciation to the following for their contributions:

- Panel of external reviewers who reviewed the draft
- Dr. Sheamini Sivasampu (Head of Healthcare Statistics Unit, Clinical Research Centre), Ms. Mariammah Krishnasamy, Scientific Officer and Ms. Sin Lian Thye, Nursing Matron
- Technical Advisory Committee for CPG and HTA-CPG Council for their valuable input and feedback
- All those who have contributed directly or indirectly to the development of the CPG

DISCLOSURE STATEMENT

The panel members had completed disclosure forms. None hold shares in pharmaceutical firms or act as consultants to such firms. (Details are available upon request from the CPG Secretariat)

SOURCES OF FUNDING

The development of the CPG on Screening of Diabetic Retinopathy was supported financially in its entirety by the Ministry of Health Malaysia.